CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014

     CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014

PR Newswire

MONMOUTH JUNCTION, N.J., March 13, 2014

MONMOUTH JUNCTION, N.J., March 13, 2014 /PRNewswire/ --CytoSorbents
Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood
purification to treat life-threatening illnesses in the intensive care unit,
announced that it will sponsor a research symposium entitled:

"SIRS and SEPSIS – New Therapy with CytoSorb®"

at the 34^th International Symposium on Intensive Care and Emergency Medicine
(ISICEM 2014) in Brussels, Belgium next week. The program is scheduled for
Wednesday, March 19, 2014 from 6:15 – 7:45 PM in the ARC room of the Square –
Brussels Meeting Center. Refreshments will be served.

Distinguished physicians will discuss the application of CytoSorb®
extracorporeal cytokine reduction in sepsis and other inflammatory conditions,
such as cardiac surgery.

  oDr. Herwig Gerlach (Berlin, Germany): "Overshooting the inflammatory
    response – The Root of all Evil?"
  oDr. John Kellum (Pittsburgh, USA): Blood purification in SIRS and Sepsis:
    A new paradigm"
  oDr. Michael Quintel (Gottingen, Germany): Clinical Experience: Severe
    sepsis/ septic shock and CytoSorb® therapy
  oDr. Karl Trager (Ulm, Germany): Clinical Experience: Post-Cardiopulmonary
    Bypass SIRS and CytoSorb® therapy.

In addition, attendees can visit CytoSorbents' exhibit booth in the Silver
Foyer, Booth S.01 from March 18-21, 2014 to learn more about CytoSorb®
immunotherapy for critical illnesses and how, through cytokine reduction, it
targets a reduction of the potentially deadly systemic inflammatory response
syndrome (SIRS) in order to prevent or treat organ failure and improve
clinical outcomes.

About ISICEM

The International Symposium on Intensive Care and Emergency Medicine is
organized by the Departments of Intensive Care and Emergency Medicine of
Erasme University Hospital, Universite Libre de Bruxelles, in association with
the Belgian Society of Intensive Care and Emergency Medicine. This annual
conference was started in 1980 and has become established as one of the
largest in its field, now attracting more than 6,000 participants from
countries worldwide. The objectives of this four-day symposium are to provide
participants with an up-to-date review of the most recent, clinically
relevant, developments in research, therapy, and management of the critically
ill. The meeting is open to all physicians, nurses, and other health
professionals with an interest in critical care or emergency medicine.

About CytoSorbents 

CytoSorbents Corporation is a critical care focused immunotherapy company
using blood purification to modulate inflammation -- with the goal of
preventing or treating multiple organ failure in life-threatening illnesses.
Organ failure is the cause of nearly half of all deaths in the intensive care
unit, with little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and effective
extracorporeal cytokine filter, designed to reduce the "cytokine storm" that
could otherwise cause massive inflammation, organ failure and death in common
critical illnesses such as sepsis, burn injury, trauma, lung injury, and
pancreatitis. These are conditions where the risk of death is extremely high,
yet no effective treatments exist. CytoSorbents' purification technologies are
based on biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture and
surface adsorption. CytoSorbents has numerous products under development based
upon this unique blood purification technology, protected by 32 issued US
patents and multiple applications pending, including HemoDefend™,
ContrastSorb, DrugSorb, and others. Additional information is available for
download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at http://www.sec.gov.

Please Click to Follow us on Facebook and Twitter

SOURCE CytoSorbents Corporation

Website: http://www.cytosorbents.com
Contact: Company Contact: Dr. Phillip Chan, MD, PhD, Chief Executive Officer,
CytoSorbents Corporation, (732) 329-8885 ext. *823, pchan@cytosorbents.com; or
Investor Contact: Amy Vogel, CytoSorbents Corporation, (732) 329-8885 ext.
*825, avogel@cytosorbents.com
 
Press spacebar to pause and continue. Press esc to stop.